北京大学基础医学院

院长论坛

　　报告题目：Brain tumor genome and metabolism and their implications in medicine

　　报告人：Hai Yan, MD, PhD

　　Associate Professor

　　Duke University Medical Center

　　Department of Pathology

　　时间：2011年 6月 27日(星期一) 下午3:00

　　地点：生化三层中厅

　　主持人：尹玉新教授

报告人简介：

　　Dr. Hai Yan is associate professor of Pathology with Tenure in Duke University Medical Center, and project leader of The Pediatric Brain Tumor Foundation Institute at Duke. Dr. Yan graduated from Beijing Medical University in 1991. He received PhD at Columbia University in 1996. He did postdoctoral training with Dr. Bert Vogelstein at Howard Hughes Medical Institute, in the Johns Hopkins University. Dr. Yan became Assistant Professor of Pathology in Duke University Medical Center in 2003 and was promoted to Associate Professor with Tenure in 2011. Through comprehensive elucidation of genetic alterations in brain tumors, Dr.Yan’s group has revealed novel genes for diagnostic, prognostic, or therapeutic purposes, as well as subclassification of patients that may preferentially respond to particular targeted therapies. Dr.Yan’s publication “IDH1 and IDH2 mutations in Gliomas" in the New England Journal of Medicine in 2009  has been cited as the most important cancer paper in the past two years by Nature Medicine.  Dr. Yan’s lab continues to shed light on important basic biological principles which underlie tumorigenesis, development and cancer metabolism. Dr. Yan’s research was recognized by numerous honors. He won Damon Runyon Cancer Research Foundation Scholar Award and Southeastern Brain Tumor Foundation Research Grant Scholar Award in 2005, Duke Brain SPORE Career Development Award from 2005 to 2008, Brain Tumor Society's 2008 Eliza Lorberbaum Chair of Research in 2008 and American Cancer Society Research Scholar Award in 2010.

　　Representative Publication:

1.        Reitman Z, Jin G, Karoly E, Spasojevic I, Yang J, Kinzler K, He Y, Bigner D, Vogelstein B, Yan H. Profiling the effects of NADP+-dependent isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) mutations on the cellular metabolome. 2011. PNAS. Feb 2 Early Edition.

　　2.     Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: Not your typical oncogenes. Cancer Cell. 2010 Mar 16; 17(3):215-6.

　　3.     Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res. 2010 Jan 1; 70(1):181-91.

　　4.     Yan H*, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas.  N Engl J Med.  2009 Feb 19;360(8):765-73.*corresponding author.

　　5.     Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26; 321(5897):1807-12.